Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 44 entries
Sorted by: Best Match Show Resources per page
Who is being referred to cancer genetic counseling? Characteristics of counselees and their referral.

Journal of community genetics

van Riel E, van Dulmen S, Ausems MG.
PMID: 22426886
J Community Genet. 2012 Oct;3(4):265-74. doi: 10.1007/s12687-012-0090-4. Epub 2012 Mar 17.

Both physician and patient play a role in the referral process for cancer genetic counseling. Access to such counseling is not optimal because some eligible patients are not being reached by current referral practice. We aimed to identify factors...

Cite
van Riel E, van Dulmen S, Ausems MG. Who is being referred to cancer genetic counseling? Characteristics of counselees and their referral. J Community Genet. 2012;3(4):265-74doi: 10.1007/s12687-012-0090-4.
van Riel, E., van Dulmen, S., & Ausems, M. G. (2012). Who is being referred to cancer genetic counseling? Characteristics of counselees and their referral. Journal of community genetics, 3(4), 265-74. https://doi.org/10.1007/s12687-012-0090-4
van Riel, E, et al. "Who is being referred to cancer genetic counseling? Characteristics of counselees and their referral." Journal of community genetics vol. 3,4 (2012): 265-74. doi: https://doi.org/10.1007/s12687-012-0090-4
van Riel E, van Dulmen S, Ausems MG. Who is being referred to cancer genetic counseling? Characteristics of counselees and their referral. J Community Genet. 2012 Oct;3(4):265-74. doi: 10.1007/s12687-012-0090-4. Epub 2012 Mar 17. PMID: 22426886; PMCID: PMC3461220.
Copy Download .nbib Format: NLM
Glycogen storage disease type II: birth prevalence agrees with predicted genotype frequency.

Community genetics

Ausems MG, ten Berg K, Kroos MA, van Diggelen OP, Wevers RA, Poorthuis BJ, Niezen-Koning KE, van der Ploeg AT, Beemer FA, Reuser AJ, Sandkuijl LA, Wokke JH.
PMID: 15181339
Community Genet. 1999;2(2):91-6. doi: 10.1159/000016192.

OBJECTIVES: To compare the overall birth prevalence of diagnosed glycogen storage disease type II (GSD II) with the predicted frequency based on mutation screening, in order to determine whether GSD II is an underdiagnosed condition, and to analyze which...

Cite
Ausems MG, ten Berg K, Kroos MA, et al. Glycogen storage disease type II: birth prevalence agrees with predicted genotype frequency. Community Genet. 1999;2(2):91-6doi: 10.1159/000016192.
Ausems, M. G., ten Berg, K., Kroos, M. A., van Diggelen, O. P., Wevers, R. A., Poorthuis, B. J., Niezen-Koning, K. E., van der Ploeg, A. T., Beemer, F. A., Reuser, A. J., Sandkuijl, L. A., & Wokke, J. H. (1999). Glycogen storage disease type II: birth prevalence agrees with predicted genotype frequency. Community genetics, 2(2), 91-6. https://doi.org/10.1159/000016192
Ausems, M G, et al. "Glycogen storage disease type II: birth prevalence agrees with predicted genotype frequency." Community genetics vol. 2,2 (1999): 91-6. doi: https://doi.org/10.1159/000016192
Ausems MG, ten Berg K, Kroos MA, van Diggelen OP, Wevers RA, Poorthuis BJ, Niezen-Koning KE, van der Ploeg AT, Beemer FA, Reuser AJ, Sandkuijl LA, Wokke JH. Glycogen storage disease type II: birth prevalence agrees with predicted genotype frequency. Community Genet. 1999;2(2):91-6. doi: 10.1159/000016192. PMID: 15181339.
Copy Download .nbib Format: NLM
Referral to cancer genetic counseling: do migrant status and patients' educational background matter?.

Journal of community genetics

van der Giessen JAM, van Riel E, Velthuizen ME, van Dulmen AM, Ausems MGEM.
PMID: 28868568
J Community Genet. 2017 Oct;8(4):303-310. doi: 10.1007/s12687-017-0326-4. Epub 2017 Sep 04.

Participation rates in cancer genetic counseling differ among populations, as patients with a lower educational background and migrant patients seem to have poorer access to it. We conducted a study to determine the present-day educational level and migrant status...

Cite
van der Giessen JAM, van Riel E, Velthuizen ME, et al. Referral to cancer genetic counseling: do migrant status and patients' educational background matter?. J Community Genet. 2017;8(4):303-310doi: 10.1007/s12687-017-0326-4.
van der Giessen, J. A. M., van Riel, E., Velthuizen, M. E., van Dulmen, A. M., & Ausems, M. G. E. M. (2017). Referral to cancer genetic counseling: do migrant status and patients' educational background matter?. Journal of community genetics, 8(4), 303-310. https://doi.org/10.1007/s12687-017-0326-4
van der Giessen, J A M, et al. "Referral to cancer genetic counseling: do migrant status and patients' educational background matter?." Journal of community genetics vol. 8,4 (2017): 303-310. doi: https://doi.org/10.1007/s12687-017-0326-4
van der Giessen JAM, van Riel E, Velthuizen ME, van Dulmen AM, Ausems MGEM. Referral to cancer genetic counseling: do migrant status and patients' educational background matter?. J Community Genet. 2017 Oct;8(4):303-310. doi: 10.1007/s12687-017-0326-4. Epub 2017 Sep 04. PMID: 28868568; PMCID: PMC5614888.
Copy Download .nbib Format: NLM
Breast cancer genetic counseling among Dutch patients from Turkish and Moroccan descent: participation determinants and perspectives of patients and healthcare professionals.

Journal of community genetics

Baars JE, van Dulmen AM, Velthuizen ME, van Riel E, Ausems MG.
PMID: 28083845
J Community Genet. 2017 Apr;8(2):97-108. doi: 10.1007/s12687-016-0290-4. Epub 2017 Jan 12.

Lower participation rates in cancer genetic counseling are observed among different ethnic minorities. The goal of our study is to gain insight into determinants of Turkish and Moroccan patients' participation in breast cancer genetic counseling and DNA testing, from...

Cite
Baars JE, van Dulmen AM, Velthuizen ME, et al. Breast cancer genetic counseling among Dutch patients from Turkish and Moroccan descent: participation determinants and perspectives of patients and healthcare professionals. J Community Genet. 2017;8(2):97-108doi: 10.1007/s12687-016-0290-4.
Baars, J. E., van Dulmen, A. M., Velthuizen, M. E., van Riel, E., & Ausems, M. G. (2017). Breast cancer genetic counseling among Dutch patients from Turkish and Moroccan descent: participation determinants and perspectives of patients and healthcare professionals. Journal of community genetics, 8(2), 97-108. https://doi.org/10.1007/s12687-016-0290-4
Baars, J E, et al. "Breast cancer genetic counseling among Dutch patients from Turkish and Moroccan descent: participation determinants and perspectives of patients and healthcare professionals." Journal of community genetics vol. 8,2 (2017): 97-108. doi: https://doi.org/10.1007/s12687-016-0290-4
Baars JE, van Dulmen AM, Velthuizen ME, van Riel E, Ausems MG. Breast cancer genetic counseling among Dutch patients from Turkish and Moroccan descent: participation determinants and perspectives of patients and healthcare professionals. J Community Genet. 2017 Apr;8(2):97-108. doi: 10.1007/s12687-016-0290-4. Epub 2017 Jan 12. PMID: 28083845; PMCID: PMC5386912.
Copy Download .nbib Format: NLM
Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMOny Study).

JMIR research protocols

Terra L, Hooning MJ, Heemskerk-Gerritsen BAM, van Beurden M, Roeters van Lennep JE, van Doorn HC, de Hullu JA, Mom C, van Dorst EBL, Mourits MJE, Slangen BFM, Gaarenstroom KN, Zillikens MC, Leiner T, van der Kolk L, Collee M, Wevers M, Ausems MGEM, van Engelen K, Berger LP, van Asperen CJ, Gomez-Garcia EB, van de Beek I, Rookus MA, Hauptmann M, Bleiker EM, Schagen SB, Aaronson NK, Maas AHEM, van Leeuwen FE.
PMID: 33480862
JMIR Res Protoc. 2021 Jan 22;10(1):e24414. doi: 10.2196/24414.

BACKGROUND: BRCA1/2 mutation carriers are recommended to undergo risk-reducing salpingo-oophorectomy (RRSO) at 35 to 45 years of age. RRSO substantially decreases ovarian cancer risk, but at the cost of immediate menopause. Knowledge about the potential adverse effects of premenopausal...

Cite
Terra L, Hooning MJ, Heemskerk-Gerritsen BAM, et al. Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMOny Study). JMIR Res Protoc. 2021;10(1):e24414doi: 10.2196/24414.
Terra, L., Hooning, M. J., Heemskerk-Gerritsen, B. A. M., van Beurden, M., Roeters van Lennep, J. E., van Doorn, H. C., de Hullu, J. A., Mom, C., van Dorst, E. B. L., Mourits, M. J. E., Slangen, B. F. M., Gaarenstroom, K. N., Zillikens, M. C., Leiner, T., van der Kolk, L., Collee, M., Wevers, M., Ausems, M. G. E. M., van Engelen, K., Berger, L. P., van Asperen, C. J., Gomez-Garcia, E. B., van de Beek, I., Rookus, M. A., Hauptmann, M., Bleiker, E. M., Schagen, S. B., Aaronson, N. K., Maas, A. H. E. M., & van Leeuwen, F. E. (2021). Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMOny Study). JMIR research protocols, 10(1), e24414. https://doi.org/10.2196/24414
Terra, Lara, et al. "Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMOny Study)." JMIR research protocols vol. 10,1 (2021): e24414. doi: https://doi.org/10.2196/24414
Terra L, Hooning MJ, Heemskerk-Gerritsen BAM, van Beurden M, Roeters van Lennep JE, van Doorn HC, de Hullu JA, Mom C, van Dorst EBL, Mourits MJE, Slangen BFM, Gaarenstroom KN, Zillikens MC, Leiner T, van der Kolk L, Collee M, Wevers M, Ausems MGEM, van Engelen K, Berger LP, van Asperen CJ, Gomez-Garcia EB, van de Beek I, Rookus MA, Hauptmann M, Bleiker EM, Schagen SB, Aaronson NK, Maas AHEM, van Leeuwen FE. Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMOny Study). JMIR Res Protoc. 2021 Jan 22;10(1):e24414. doi: 10.2196/24414. PMID: 33480862; PMCID: PMC7864779.
Copy Download .nbib Format: NLM
Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study.

Breast (Edinburgh, Scotland)

Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, Steyerberg EW, Hauptmann M, van de Beek I, van Engelen K, Wevers MR, Gómez García EB, Ausems MGEM, Berger LPV, van Asperen CJ, Adank MA, Collée MJ, Stommel-Jenner DJ, Jager A, Schmidt MK, Hooning MJ.
PMID: 34929424
Breast. 2021 Dec 14;61:98-107. doi: 10.1016/j.breast.2021.12.007. Epub 2021 Dec 14.

AIM: BRCA1/2 mutation carriers with primary breast cancer (PBC) are at high risk of contralateral breast cancer (CBC). In a nationwide cohort, we investigated the effects of chemotherapeutic agents given for PBC on CBC risk separately in BRCA1 and...

Cite
Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, et al. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. Breast. 2021;61:98-107doi: 10.1016/j.breast.2021.12.007.
Akdeniz, D., van Barele, M., Heemskerk-Gerritsen, B. A. M., Steyerberg, E. W., Hauptmann, M., van de Beek, I., van Engelen, K., Wevers, M. R., Gómez García, E. B., Ausems, M. G. E. M., Berger, L. P. V., van Asperen, C. J., Adank, M. A., Collée, M. J., Stommel-Jenner, D. J., Jager, A., Schmidt, M. K., & Hooning, M. J. (2021). Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. Breast (Edinburgh, Scotland), 6198-107. https://doi.org/10.1016/j.breast.2021.12.007
Akdeniz, Delal, et al. "Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study." Breast (Edinburgh, Scotland) vol. 61 (2021): 98-107. doi: https://doi.org/10.1016/j.breast.2021.12.007
Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, Steyerberg EW, Hauptmann M, van de Beek I, van Engelen K, Wevers MR, Gómez García EB, Ausems MGEM, Berger LPV, van Asperen CJ, Adank MA, Collée MJ, Stommel-Jenner DJ, Jager A, Schmidt MK, Hooning MJ. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. Breast. 2021 Dec 14;61:98-107. doi: 10.1016/j.breast.2021.12.007. Epub 2021 Dec 14. PMID: 34929424.
Copy Download .nbib Format: NLM
The tumor microenvironment and radiotherapy response; a central role for cancer-associated fibroblasts.

Clinical and translational radiation oncology

Ansems M, Span PN.
PMID: 32337377
Clin Transl Radiat Oncol. 2020 Apr 13;22:90-97. doi: 10.1016/j.ctro.2020.04.001. eCollection 2020 May.

Tumor growth is not only dictated by events involving tumor cells, but also by the environment they reside in, the so-called tumor microenvironment (TME). In the TME, cancer-associated fibroblasts (CAFs) are often the predominant cell type. CAFs were long...

Cite
Ansems M, Span PN. The tumor microenvironment and radiotherapy response; a central role for cancer-associated fibroblasts. Clin Transl Radiat Oncol. 2020;22:90-97doi: 10.1016/j.ctro.2020.04.001.
Ansems, M., & Span, P. N. (2020). The tumor microenvironment and radiotherapy response; a central role for cancer-associated fibroblasts. Clinical and translational radiation oncology, 2290-97. https://doi.org/10.1016/j.ctro.2020.04.001
Ansems, Marleen, and Span, Paul N. "The tumor microenvironment and radiotherapy response; a central role for cancer-associated fibroblasts." Clinical and translational radiation oncology vol. 22 (2020): 90-97. doi: https://doi.org/10.1016/j.ctro.2020.04.001
Ansems M, Span PN. The tumor microenvironment and radiotherapy response; a central role for cancer-associated fibroblasts. Clin Transl Radiat Oncol. 2020 Apr 13;22:90-97. doi: 10.1016/j.ctro.2020.04.001. eCollection 2020 May. PMID: 32337377; PMCID: PMC7177030.
Copy Download .nbib Format: NLM
Genotyping and Characterization of HPV Status, Hypoxia, and Radiosensitivity in 22 Head and Neck Cancer Cell Lines.

Cancers

Göttgens EL, Ansems M, Leenders WPJ, Bussink J, Span PN.
PMID: 33802339
Cancers (Basel). 2021 Mar 03;13(5). doi: 10.3390/cancers13051069.

To study head and neck squamous cell carcinomas (HNSCC) in vitro, a large variety of HNSCC cell lines have been developed. Here, we characterize a panel of 22 HNSCC cell lines, thereby providing a tool for research into tumor-specific...

Cite
Göttgens EL, Ansems M, Leenders WPJ, et al. Genotyping and Characterization of HPV Status, Hypoxia, and Radiosensitivity in 22 Head and Neck Cancer Cell Lines. Cancers (Basel). 2021;13(5)doi: 10.3390/cancers13051069.
Göttgens, E. L., Ansems, M., Leenders, W. P. J., Bussink, J., & Span, P. N. (2021). Genotyping and Characterization of HPV Status, Hypoxia, and Radiosensitivity in 22 Head and Neck Cancer Cell Lines. Cancers, 13(5), . https://doi.org/10.3390/cancers13051069
Göttgens, Eva-Leonne, et al. "Genotyping and Characterization of HPV Status, Hypoxia, and Radiosensitivity in 22 Head and Neck Cancer Cell Lines." Cancers vol. 13,5 (2021). doi: https://doi.org/10.3390/cancers13051069
Göttgens EL, Ansems M, Leenders WPJ, Bussink J, Span PN. Genotyping and Characterization of HPV Status, Hypoxia, and Radiosensitivity in 22 Head and Neck Cancer Cell Lines. Cancers (Basel). 2021 Mar 03;13(5). doi: 10.3390/cancers13051069. PMID: 33802339; PMCID: PMC7959143.
Copy Download .nbib Format: NLM
Reproductive decision-making in the context of hereditary cancer: the effects of an online decision aid on informed decision-making.

Journal of community genetics

Reumkens K, Tummers MHE, Severijns Y, Gietel-Habets JJG, van Kuijk SMJ, Aalfs CM, van Asperen CJ, Ausems MGEM, Collée M, Dommering CJ, Kets M, van der Kolk LE, Oosterwijk JC, Tjan-Heijnen VCG, van der Weijden T, de Die-Smulders CEM, van Osch LADM.
PMID: 32880035
J Community Genet. 2021 Jan;12(1):101-110. doi: 10.1007/s12687-020-00484-2. Epub 2020 Sep 02.

Individuals having a genetic predisposition to cancer and their partners face challenging decisions regarding their wish to have children. This study aimed to determine the effects of an online decision aid to support couples in making an informed decision...

Cite
Reumkens K, Tummers MHE, Severijns Y, et al. Reproductive decision-making in the context of hereditary cancer: the effects of an online decision aid on informed decision-making. J Community Genet. 2020;12(1):101-110doi: 10.1007/s12687-020-00484-2.
Reumkens, K., Tummers, M. H. E., Severijns, Y., Gietel-Habets, J. J. G., van Kuijk, S. M. J., Aalfs, C. M., van Asperen, C. J., Ausems, M. G. E. M., Collée, M., Dommering, C. J., Kets, M., van der Kolk, L. E., Oosterwijk, J. C., Tjan-Heijnen, V. C. G., van der Weijden, T., de Die-Smulders, C. E. M., & van Osch, L. A. D. M. (2021). Reproductive decision-making in the context of hereditary cancer: the effects of an online decision aid on informed decision-making. Journal of community genetics, 12(1), 101-110. https://doi.org/10.1007/s12687-020-00484-2
Reumkens, Kelly, et al. "Reproductive decision-making in the context of hereditary cancer: the effects of an online decision aid on informed decision-making." Journal of community genetics vol. 12,1 (2021): 101-110. doi: https://doi.org/10.1007/s12687-020-00484-2
Reumkens K, Tummers MHE, Severijns Y, Gietel-Habets JJG, van Kuijk SMJ, Aalfs CM, van Asperen CJ, Ausems MGEM, Collée M, Dommering CJ, Kets M, van der Kolk LE, Oosterwijk JC, Tjan-Heijnen VCG, van der Weijden T, de Die-Smulders CEM, van Osch LADM. Reproductive decision-making in the context of hereditary cancer: the effects of an online decision aid on informed decision-making. J Community Genet. 2021 Jan;12(1):101-110. doi: 10.1007/s12687-020-00484-2. Epub 2020 Sep 02. PMID: 32880035; PMCID: PMC7846643.
Copy Download .nbib Format: NLM
European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer.

Annals of oncology : official journal of the European Society for Medical Oncology

Vergote I, González-Martín A, Ray-Coquard I, Harter P, Colombo N, Pujol P, Lorusso D, Mirza MR, Brasiuniene B, Madry R, Brenton JD, Ausems MGEM, Büttner R, Lambrechts D.
PMID: 34861371
Ann Oncol. 2021 Dec 01; doi: 10.1016/j.annonc.2021.11.013. Epub 2021 Dec 01.

BACKGROUND: Homologous recombination repair (HRR) enables fault-free repair of double-stranded DNA breaks. HRR deficiency is predicted to occur in around half of high-grade serous ovarian carcinomas. Ovarian cancers harbouring HRR deficiency typically exhibit sensitivity to poly-ADP ribose polymerase inhibitors...

Cite
Vergote I, González-Martín A, Ray-Coquard I, et al. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. Ann Oncol. 2021;doi: 10.1016/j.annonc.2021.11.013.
Vergote, I., González-Martín, A., Ray-Coquard, I., Harter, P., Colombo, N., Pujol, P., Lorusso, D., Mirza, M. R., Brasiuniene, B., Madry, R., Brenton, J. D., Ausems, M. G. E. M., Büttner, R., Lambrechts, D. (2021). European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. Annals of oncology : official journal of the European Society for Medical Oncology, . https://doi.org/10.1016/j.annonc.2021.11.013
Vergote, I, et al. "European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer." Annals of oncology : official journal of the European Society for Medical Oncology vol. (2021). doi: https://doi.org/10.1016/j.annonc.2021.11.013
Vergote I, González-Martín A, Ray-Coquard I, Harter P, Colombo N, Pujol P, Lorusso D, Mirza MR, Brasiuniene B, Madry R, Brenton JD, Ausems MGEM, Büttner R, Lambrechts D. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. Ann Oncol. 2021 Dec 01; doi: 10.1016/j.annonc.2021.11.013. Epub 2021 Dec 01. PMID: 34861371.
Copy Download .nbib Format: NLM
Timeline of development of pancreatic cancer and implications for successful early detection in high-risk individuals.

Gastroenterology

Overbeek KA, Goggins MG, Dbouk M, Levink IJM, Koopmann BDM, Chuidian M, Konings ICAW, Paiella S, Earl J, Fockens P, Gress TM, Ausems MGEM, Poley JW, Thosani NC, Half E, Lachter J, Stoffel EM, Kwon RS, Stoita A, Kastrinos F, Lucas AL, Syngal S, Brand RE, Chak A, Carrato A, Vleggaar FP, Bartsch DK, van Hooft JE, Cahen DL, Canto MI, Bruno MJ.
PMID: 34678218
Gastroenterology. 2021 Oct 19; doi: 10.1053/j.gastro.2021.10.014. Epub 2021 Oct 19.

BACKGROUND AND AIMS: To successfully implement imaging-based pancreatic cancer (PC) surveillance, it is key to understand the timeline and morphological features of neoplastic progression. We aimed to investigate the progression to neoplasia from serial prediagnostic pancreatic imaging tests in...

Cite
Overbeek KA, Goggins MG, Dbouk M, et al. Timeline of development of pancreatic cancer and implications for successful early detection in high-risk individuals. Gastroenterology. 2021;doi: 10.1053/j.gastro.2021.10.014.
Overbeek, K. A., Goggins, M. G., Dbouk, M., Levink, I. J. M., Koopmann, B. D. M., Chuidian, M., Konings, I. C. A. W., Paiella, S., Earl, J., Fockens, P., Gress, T. M., Ausems, M. G. E. M., Poley, J. W., Thosani, N. C., Half, E., Lachter, J., Stoffel, E. M., Kwon, R. S., Stoita, A., Kastrinos, F., Lucas, A. L., Syngal, S., Brand, R. E., Chak, A., Carrato, A., Vleggaar, F. P., Bartsch, D. K., van Hooft, J. E., Cahen, D. L., Canto, M. I., Bruno, M. J. (2021). Timeline of development of pancreatic cancer and implications for successful early detection in high-risk individuals. Gastroenterology, . https://doi.org/10.1053/j.gastro.2021.10.014
Overbeek, Kasper A, et al. "Timeline of development of pancreatic cancer and implications for successful early detection in high-risk individuals." Gastroenterology vol. (2021). doi: https://doi.org/10.1053/j.gastro.2021.10.014
Overbeek KA, Goggins MG, Dbouk M, Levink IJM, Koopmann BDM, Chuidian M, Konings ICAW, Paiella S, Earl J, Fockens P, Gress TM, Ausems MGEM, Poley JW, Thosani NC, Half E, Lachter J, Stoffel EM, Kwon RS, Stoita A, Kastrinos F, Lucas AL, Syngal S, Brand RE, Chak A, Carrato A, Vleggaar FP, Bartsch DK, van Hooft JE, Cahen DL, Canto MI, Bruno MJ. Timeline of development of pancreatic cancer and implications for successful early detection in high-risk individuals. Gastroenterology. 2021 Oct 19; doi: 10.1053/j.gastro.2021.10.014. Epub 2021 Oct 19. PMID: 34678218.
Copy Download .nbib Format: NLM
Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study.

Breast (Edinburgh, Scotland)

Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, Steyerberg EW, Hauptmann M, van de Beek I, van Engelen K, Wevers MR, Gómez García EB, Ausems MGEM, Berger LPV, van Asperen CJ, Adank MA, Collée MJ, Stommel-Jenner DJ, Jager A, Schmidt MK, Hooning MJ.
PMID: 34929424
Breast. 2021 Dec 14;61:98-107. doi: 10.1016/j.breast.2021.12.007. Epub 2021 Dec 14.

AIM: BRCA1/2 mutation carriers with primary breast cancer (PBC) are at high risk of contralateral breast cancer (CBC). In a nationwide cohort, we investigated the effects of chemotherapeutic agents given for PBC on CBC risk separately in BRCA1 and...

Cite
Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, et al. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. Breast. 2021;61:98-107doi: 10.1016/j.breast.2021.12.007.
Akdeniz, D., van Barele, M., Heemskerk-Gerritsen, B. A. M., Steyerberg, E. W., Hauptmann, M., van de Beek, I., van Engelen, K., Wevers, M. R., Gómez García, E. B., Ausems, M. G. E. M., Berger, L. P. V., van Asperen, C. J., Adank, M. A., Collée, M. J., Stommel-Jenner, D. J., Jager, A., Schmidt, M. K., & Hooning, M. J. (2021). Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. Breast (Edinburgh, Scotland), 6198-107. https://doi.org/10.1016/j.breast.2021.12.007
Akdeniz, Delal, et al. "Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study." Breast (Edinburgh, Scotland) vol. 61 (2021): 98-107. doi: https://doi.org/10.1016/j.breast.2021.12.007
Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, Steyerberg EW, Hauptmann M, van de Beek I, van Engelen K, Wevers MR, Gómez García EB, Ausems MGEM, Berger LPV, van Asperen CJ, Adank MA, Collée MJ, Stommel-Jenner DJ, Jager A, Schmidt MK, Hooning MJ. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. Breast. 2021 Dec 14;61:98-107. doi: 10.1016/j.breast.2021.12.007. Epub 2021 Dec 14. PMID: 34929424; PMCID: PMC8693290.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 44 entries